Pharmacokinetic analysis of erlotinib and OSI-420 in pediatric patients with malignant gliomas.

被引：0
|
作者：
Schaiquevich, P. [1 ]
Panetta, J. C. [1 ]
Throm, S. [1 ]
Bai, F. [1 ]
Broniscer, A. [1 ]
Stewart, C. [1 ]
机构：
[1] St Jude Childrens Hosp, Memphis, TN 38105 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S50 / S50
页数：1
相关论文
共 50 条
  • [1] Effects of omeprazole and esomeprazole on the pharmacokinetics of erlotinib and its metabolite OSI-420 in rats
    Zheng, Xiaokang
    Li, Shuanglong
    Xue, Linlin
    Mo, Changhao
    Chen, Lijun
    Guo, Xue
    Zhao, Zerui
    Qiu, Xiangjun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (04): : 6896 - 6901
  • [2] Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420
    Broniscer, Alberto
    Panetta, John C.
    O'Shaughnessy, Melinda
    Fraga, Charles
    Bai, Feng
    Krasin, Matthew J.
    Gajjar, Amar
    Stewart, Clinton F.
    CLINICAL CANCER RESEARCH, 2007, 13 (05) : 1511 - 1515
  • [3] Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors
    Reddick, Samuel J.
    Campagne, Olivia
    Huang, Jie
    Onar-Thomas, Arzu
    Broniscer, Alberto
    Gajjar, Amar
    Stewart, Clinton F.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 829 - 838
  • [4] The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry
    Masters, Andrea R.
    Sweeney, Christopher J.
    Jones, David R.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 848 (02): : 379 - 383
  • [5] Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors
    Samuel J. Reddick
    Olivia Campagne
    Jie Huang
    Arzu Onar-Thomas
    Alberto Broniscer
    Amar Gajjar
    Clinton F. Stewart
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 829 - 838
  • [6] Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors
    Samuel J. Reddick
    Olivia Campagne
    Jie Huang
    Arzu Onar-Thomas
    Alberto Broniscer
    Amar Gajjar
    Clinton F. Stewart
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 475 - 475
  • [7] A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma
    Svedberg, Anna
    Green, Henrik
    Vikstrom, Anders
    Lundeberg, Joakim
    Vikingsson, Svante
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2015, 107 : 186 - 195
  • [8] The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates
    Meany, Holly J.
    Fox, Elizabeth
    McCully, Cynthia
    Tucker, Chris
    Balis, Frank M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) : 387 - 392
  • [9] The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates
    Holly J. Meany
    Elizabeth Fox
    Cynthia McCully
    Chris Tucker
    Frank M. Balis
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 387 - 392
  • [10] Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors (vol 84, 829, 2019)
    Reddick, Samuel
    Campagne, Olivia
    Huang, Jie
    Onar-Thomas, Arzu
    Broniscer, Alberto
    Gajjar, Amar
    Stewart, Clinton F.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (02) : 475 - 475
12345